Clinical Trial Update: Evaluating the Safety and Immune Response to Two Admixtures of a Tetravalent Dengue Virus Vaccine [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety and immune responses to two admixtures of a tetravalent dengue virus vaccine; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue

Drugs mentioned

• Tetravalent dengue vaccine (experimental) (tetravalent dengue vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue | Phase 1 | Status: COMPLETED